Home Recalls D-0542-2024
Class III · Low risk Ongoing Initiated May 16, 2024 (2 years ago)
Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by…
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Why it was recalled
Failed Impurities/Degradation Specifications.
What was recalled
Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1192-8
Recalling firm Zydus Pharmaceuticals (USA) Inc
NDC code 70710-1192-8
Origin NJ, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-0542-2024
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class II · Moderate risk Ongoing May 27, 2026
Reason Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Class II · Moderate risk Ongoing May 12, 2026
Reason Defective Container; packets were found to be either empty or partially full.
Class II · Moderate risk Ongoing Jan 26, 2026
Reason Presence of Foreign substance - potential presence of metal particulate matter
Class II · Moderate risk Ongoing Jan 26, 2026
Reason Presence of Foreign substance - potential presence of metal particulate matter
Class II · Moderate risk Ongoing Jan 26, 2026
Reason Presence of Foreign substance - potential presence of metal particulate matter